{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:46:51Z","timestamp":1788295611887,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clinthera.2017.11.011","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T18:23:28Z","timestamp":1514312608000},"page":"156-165.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis"],"prefix":"10.1016","volume":"40","author":[{"given":"David L.","family":"Gossage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Cieslarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophe","family":"Ap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Sundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.11.011_bib1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib2","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib3","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2017.11.011_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2017.11.011_bib5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/rheumatology\/kel253","article-title":"Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis","volume":"46","author":"Young","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2017.11.011_bib6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.11.011_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib8","first-page":"S136","article-title":"Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2017.11.011_bib9","doi-asserted-by":"crossref","first-page":"b702","DOI":"10.1136\/bmj.b702","article-title":"Management of rheumatoid arthritis: summary of NICE guidance","volume":"338","author":"Deighton","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2017.11.011_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2017.11.011_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.62.11.1094","article-title":"Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis","volume":"62","author":"Tchetverikov","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/40.3.247","article-title":"Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis","volume":"40","author":"Kaneko","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2017.11.011_bib13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.1780390919","article-title":"Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis","volume":"39","author":"Ahrens","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2017.11.011_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/ard.59.6.455","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis","volume":"59","author":"Yoshihara","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2308","article-title":"Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases","volume":"6","author":"Hu","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2017.11.011_bib16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/jlb.57.5.774","article-title":"Matrix metalloproteinases and processing of pro-TNF-alpha","volume":"57","author":"Gearing","year":"1995","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clinthera.2017.11.011_bib17","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/rheumatology\/keu254","article-title":"Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation","volume":"53","author":"Xue","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2017.11.011_bib18","doi-asserted-by":"crossref","first-page":"13066","DOI":"10.1074\/jbc.274.19.13066","article-title":"Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin\/stromelysin-1 cascade enhances tumor cell invasion","volume":"274","author":"Ramos-DeSimone","year":"1999","journal-title":"J Biol Chem"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2017.11.011_bib19","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1136\/ard.61.suppl_2.ii43","article-title":"Treatments no longer in development for rheumatoid arthritis","volume":"61","author":"Keystone","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib20","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2315","article-title":"Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study","volume":"9","author":"Krzeski","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2017.11.011_bib21","doi-asserted-by":"crossref","first-page":"e0127063","DOI":"10.1371\/journal.pone.0127063","article-title":"Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer","volume":"10","author":"Marshall","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2017.11.011_bib22","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1074\/jbc.M116.760579","article-title":"Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9","volume":"292","author":"Appleby","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2017.11.011_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2017.11.011_bib24","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4.03","year":"2010","journal-title":"NIH Publication No. 09-5410"},{"key":"10.1016\/j.clinthera.2017.11.011_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib26","first-page":"S-29","article-title":"Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis","volume":"32","author":"Segurado","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2017.11.011_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","article-title":"Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials","volume":"74","author":"Ward","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.11.011_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2017.11.011_bib29","first-page":"4030","article-title":"Phase 1 study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors","author":"Bendell","year":"2015","journal-title":"2015 ASCO Annual Meeting"},{"key":"10.1016\/j.clinthera.2017.11.011_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/apt.13653","article-title":"Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis","volume":"44","author":"Sandborn","year":"2016","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817311025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817311025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T17:03:50Z","timestamp":1530205430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817311025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0149291817311025"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}